<DOC>
	<DOCNO>NCT02362672</DOCNO>
	<brief_summary>The purpose study determine whether new opioid molecule , NKTR-181 , effective relief moderate severe chronic low back pain compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Study NKTR-181 Opioid-Naive Subjects With Low Back Pain</brief_title>
	<detailed_description>This enriched enrollment , randomize withdrawal study open label , dose-titration period follow randomized , double-blind , placebo-control treatment twelve week . During double-blind treatment period , study evaluate analgesic effect NKTR-181 versus placebo patient moderate severe chronic low back pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Male nonpregnant , nonnursing female age 18 75 year old Clinical diagnosis moderate severe , chronic nonneuropathic low back pain least six month Not experience adequate pain relief fail previous treatment nonopioid analgesic Opioid analgesia necessary Currently take 10 mg morphine sulfate equivalent per day short act opioids 14 day prior entry Females child bear potential must use highly effective form birth control . All subject must agree use doublebarrier contraception participation study least 2 month last dose study drug . Willing able provide inform consent Taking extended release longacting opioids within 6 month History hypersensitivity , intolerance , allergy opioids Compression spinal nerve root ; spinal fracture , tumor , abscess Surgical procedure low back last 12 month facet nerve root block radiofrequency ablation last 3 month Untreated moderate severe sleep apnea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>